Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324062 · ClinicalTrials.gov registry record
Cancer Genetics Hereditary Cancer Panel Testing
A clinical trial, sponsored by University of Southern California.
- Completed
- Registry status
- 1,511
- Enrollment target
NCT02324062: Completed study, sponsored by University of Southern California.
NCT02324062 is a clinical trial that has completed, run by University of Southern California. The registered enrollment target is 1,511 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02324062 has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 1,511 participants
- Enrollment target
Study Summary
This study is about understanding the use of a genetic test (Myriad Genetics myRisk panel) that analyzes 25 genes related to different hereditary cancer conditions. The investigators hope to learn more about how this type of genetic test is used clinically. The investigators also hope to understand more about the experience of individuals and families who undergoing this test of genetic testing.
Primary Outcome
Develop a resource (repository and database) with banked specimens, HCP panel results, pre-clinical and follow up information and impact of the HCP results
Interventions
- OTHER Questionnaires
- OTHER Blood Draw and Baseline Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,511 participants |
| Start Date | 2014-06-12 |
| Est. Completion | 2020-08-31 |
What the finished NCT02324062 record still lists
NCT02324062 is an observational study that tracks outcomes without assigning an intervention. Its 1,511 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Questionnaires is the first listed.
NCT02324062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02324062 about?
NCT02324062 is a clinical study titled "Cancer Genetics Hereditary Cancer Panel Testing". This study is about understanding the use of a genetic test (Myriad Genetics myRisk panel) that analyzes 25 genes related to different hereditary cancer conditions. The investigators hope to learn more about how this type of genetic test is used clinically. The investigators also hope to understand ...
What is the current status of trial NCT02324062?
This trial is currently completed. The enrollment target is 1,511 participants. The study started on 2014-06-12. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT02324062?
The interventions under investigation include: Questionnaires (OTHER), Blood Draw and Baseline Questionnaire (OTHER).
Who is sponsoring clinical trial NCT02324062?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI